Unlocking therapeutic frontiers: harnessing artificial intelligence in drug discovery for neurodegenerative diseases.

Journal: Drug discovery today
PMID:

Abstract

Neurodegenerative diseases (NDs) pose serious healthcare challenges with limited therapeutic treatments and high social burdens. The integration of artificial intelligence (AI) into drug discovery has emerged as a promising approach to address these challenges. This review explores the application of AI techniques to unravel therapeutic frontiers for NDs. We examine the current landscape of AI-driven drug discovery and discuss the potentials of AI in accelerating the identification of novel therapeutic targets on ND research and drug development, optimization of drug candidates, and expediating personalized medicine approaches. Finally, we outline future directions and challenges in harnessing AI for the advancement of therapeutics in this critical area by emphasizing the importance of interdisciplinary collaboration and ethical considerations.

Authors

  • Bilal Nehmeh
    Department of Physical Sciences, Lebanese American University, Beirut 1102-2801, Lebanon.
  • Joseph Rebehmed
    Department of Computer Science and Mathematics, Lebanese American University, Beirut 1102-2801, Lebanon.
  • Riham Nehmeh
    INSA Rennes, Institut d'électronique et de Télécommunications de Rennes IETR, UMR 6164, 35708 Rennes, France.
  • Robin Taleb
    Department of Physical Sciences, Lebanese American University, Byblos Campus, Blat, 4M8F+6QF, Lebanon.
  • Elias Akoury
    Department of Physical Sciences, Lebanese American University, Beirut 1102-2801, Lebanon. Electronic address: elias.akoury@lau.edu.lb.